ReviewCurrent pharmaceutical biotechnology2025
Genome Editing Approaches Using Zinc Finger Nucleases (ZFNs) for the Treatment of Motor Neuron Diseases.
Review in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Zinc finger proteins (ZFPs) in health and disease.Molecular biomedicine · 2026Review
- Biomarkers as Drivers of Innovation in Modern Diagnostics and Therapeutics.Current drug targets · 2026Review
- Exploring the Therapeutic Potential of Plant-Based Natural Products in Combating Aging.Current drug targets · 2026Review
- Watermelon Rind: Nutritional Composition, Therapeutic Potential, Environmental Impact, and Commercial Applications in Sustainable Industries.Current pharmaceutical design · 2026Review
- Emerging Combinatorial Drug Delivery Strategies for Breast Cancer: A Comprehensive Review.Current drug targets · 2025Review
- Lipidomics in Breast Cancer: Decoding Metabolic Reprogramming and Unlocking Therapeutic Opportunities.Current drug targets · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motor neuron disorders encompass a spectrum of conditions that can be inherited or arise from spontaneous gene mutations. These disorders disrupt the crucial connection between motor neurons and muscles, leading to a range of symptoms, including muscle weakness, impaired coordination, and abnormal movements. Unfortunately, despite the significant impact on individuals' quality of life, there is currently no definitive cure for these disorders. In response to this pressing medical need, extensive research efforts are underway globally to develop effective treatments for motor neuron disorders. Among the emerging therapeutic strategies, gene therapy has shown considerable promise. By targeting the underlying genetic abnormalities responsible for these disorders, gene therapy aims to correct or mitigate the dysfunctional molecular pathways, offering hope for improved outcomes and potentially even disease reversal. Various approaches are being explored within the realm of gene therapy, with genetic modification techniques taking center stage. These techniques enable precise manipulation of the genetic material, facilitating the replacement of mutated genes with functional ones. One such technique that has garnered attention for its potential therapeutic efficacy is Zinc Finger Nucleases (ZFNs). ZFNs are molecular tools designed to target specific DNA sequences with high precision, enabling targeted gene editing. Their ability to induce targeted modifications in the genome holds significant promise for treating motor neuron disorders by correcting diseasecausing mutations. Moreover, ZFNs offer advantages such as accuracy and desirable therapeutic effects, making them an attractive option for gene therapy applications. Despite their potential, it is essential to acknowledge the limitations and challenges associated with ZFN-based gene therapy. These include off-target effects, delivery methods, and immune responses. Understanding and addressing these challenges are critical steps toward realizing the full therapeutic potential of ZFNs in treating motor neuron disorders. In this comprehensive review, we delve into the intricacies of ZFNs, exploring their mechanisms of action, current applications, limitations, and future prospects in gene therapy for motor neuron disorders. Additionally, we provide insights into other nucleases-mediated gene therapy approaches, highlighting their comparative advantages and challenges. Furthermore, we discuss factors influencing the efficacy and safety of gene therapy treatments, including delivery methods, immune responses, and ethical considerations. By examining these factors in detail, we aim to provide a holistic understanding of the complex landscape of gene therapy for motor neuron disorders and pave the way for future advancements in the field.
Indexed as
Identifiers
38847163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.